The objective of this study was to construct a modified equation for the delivery of a drug by iontophoresis. Indomethacin was selected as a model since it has been widely used as a non-steroidal anti-inflammatory drug (NSAID) for external pharmaceutical preparations. The experiments were performed under a constant current in vivo using rat abdominal skin, and the plasma concentration was monitored by HPLC. Pharmacokinetic parameters were obtained from the plasma concentration profiles after intravenous injection. A theoretical value of the transdermal delivery of drug by iontophoresis was calculated from the plasma concentration and pharmacokinetic parameters. The experimental value was evidently higher than the theoretical one, suggesting the enhancement of passive diffusion with an increase of applied current. The modified equation was proposed for the delivery of a drug by iontophoresis incorporating enhanced passive diffusion.
The stratum corneum, the outermost layer of the skin, acts as a barrier. It is therefore necessary to disrupt this function to improve the transdermal delivery of a drug. We focused on iontophoresis as a physical method by which ionic drugs migrate by electric potential. 1) It is known that the barrier function of skin is disturbed by iontophoresis. [2] [3] [4] The delivery of drugs by iontophoresis has been evaluated using the Nernst-Planck equation, 5, 6) the modified Nernst-Planck equation, [7] [8] [9] the efficiency of drug delivery calculated from the delivery rate [10] [11] [12] and the migration in blood circulation based on the pharmacokinetics of drugs. 13) The migration of a drug on the application of a current has been analyzed in detail with these methods. But little attention has been paid to passive diffusion caused by a reduction in the skin barrier function. It is well known that a disruption of the barrier function enhances the passive diffusion of a drug through the skin. 14, 15) In this study, the migration of a drug by iontophoresis was quantitatively evaluated taking into consideration a reduction in the barrier function of skin. An iontophoretic transdermal delivery experiment was carried out in vivo using rat abdominal skin. Moreover, pharmacokinetic parameters were calculated to estimate the efficiency of drug delivery [10] [11] [12] based on Faraday's law.
Indomethacin was selected as a model drug since it has been widely used as a non-steroidal anti-inflammatory drug (NSAID) for external pharmaceutical preparations. Additionally, an enhanced transdermal delivery of indomethacin is considered to be effective in the treatment of rheumatoid arthritis.
THEORETICAL
For the rate and efficiency of transdermal delivery of a drug by current application, Phipps et al., 10) Sage et al. 11) and Singh et al. 12) have derived a theory based on Faraday's law. We proposed a modified equation to incorporate an enhanced passive diffusion due to a reduction in the barrier function of the skin.
The mol number of electrons which pass through the external circuit per second, Ne, is derived from Faraday's law:
where, I is the current (A), and F is Faraday's constant (96487 C/mol) (1 A equals to 1 C/s). The efficiency of drug delivery, Ed, is defined as:
EdϭNi/NeϭF Ni/I (2) where, Ni is the number of moles of drug ion which cross the skin per unit of time during current application. The drug delivery rate due to current application, Rc, is calculated as:
where, Mw is the molecular weight of the drug ion. Combining Eqs. 2 and 3 yields:
The drug delivery rate by iontophoresis, R, is given as the sum of passive diffusion, Rp, and current application, Rc:
RcϭMw Ed I/FϭFi I (7) where, k is the constant which represents the migration of drug by enhanced passive diffusion. RЈp is the drug delivery rate by passive diffusion (without current):
EdϭF Fi/Mw (9) where, Fi is the flux (mg/h/mA) which defines the amount of drug delivered per unit of time and current. C is the plasma concentration (mg/ml/mA) per current and CL is the systemic clearance (ml/h). Finally, the amount of drug delivered by iontophoresis, M, at processing time, T, is defined as:
MATERIALS AND METHODS

Materials and Animals
Idomethine KOWA Sol prepared from indomethacin (1%) L-menthol (0.3%), propylene glycol (6%), macrogol 300 (6%), diisopropyl adipate (5%), isopropyl alcohol (40%) and purified water was purchased from Kowa Co. Ltd. (Aichi, Japan). All other commercially available chemicals were obtained from dealers. Male Wistar rats (eight weeks old, 200-230 g) were purchased from Charles River Japan, Inc. (Tokyo, Japan).
Pharmacokinetic Parameter Idomethine KOWA Sol (1 ml) was administered to the rats by intravenous injection. After an appropriate period, blood samples (1 ml) were collected. The blood was centrifuged at 3000 rpm for 10 min, and the plasma (0.5 ml) analyzed by HPLC. The area under the plasma concentration-time curve (AUC ) was calculated by the trapezoidal method, and systemic clearance was calculated from the AUC using Microsoft Excell 97 for Windows.
Transdermal Delivery in Vivo The rats were anesthetized with an intraperitoneal injection of pentobarbital (0.05 mg/g) and their abdominal hair was clipped. Two sheets of non-woven fabric (4 cm 2 ) were placed on the abdominal skin 1 cm apart. Idomethine KOWA Sol (0.5 ml) and saline (0.5 ml) were injected into the cathodal and anodal fabric, respectively. Aluminum electrodes were attached to the fabrics, and cathodal iontophoresis was performed at constant current (0.3-1 mA) using a DC voltage current generator (model 2555 or 2554, Yokogawa Electric Co., Tokyo, Japan) as shown in Fig. 1 . The range of current density was 0 to 0.25 mA/cm 2 . The voltage and the current were monitored by a digital multimeter (model 7552, Yokogawa Electric Co., Tokyo, Japan). Blood samples were collected at an appropriate period and the plasma was analyzed as in the pharmacokinetic experiment.
HPLC Analysis The plasma samples (0.5 ml) were extracted with toluene (5 ml) after adding 0.5 M citric acid buffer (1 ml, pH 5) and aqueous flufenamic acid solution (400 ng/ml, 1 ml, as internal standard). The toluene phase was evaporated at 60°C under a stream of nitrogen gas. The samples for HPLC thus obtained were dissolved in the mobile phase (0.5 ml). The HPLC system comprised a model DGU-12A degasser, model SCL-10A system controller, model SIL-10A auto injector, model LC-10AD pump, model SPD-10A UV-VIS detector, model CTO-10A column oven and C-R7A chromatopac (SHIMADZU, Kyoto, Japan). The column used was 4.6ϫ250 mm Develosil ODS-7 (Nomura Chemical, Aichi, Japan). The mobile phase consisted of acetonitrile-0.1 M acetic acid (60 : 40, v/v) delivered at a flowrate of 1.0 ml/min. The temperature of the column oven was set at 40°C. The amount of indomethacin in the plasma was determined at 320 nm.
RESULTS AND DISCUSSION
The total amount of drug delivered through iontophoresis may consist of the sum of that delivered by passive diffusion and by current application. In this study, the theoretical values of drug absorption were compared to the experimental values. Theoretical values were calculated from the equation proposed by Phipps et al. 10) using the flux and the efficiency of drug delivery. The experimental value was obtained from the sum of the drug amounts in the skin, muscle and plasma, determined for in vivo transdermal delivery. Moreover, a modified equation for drug delivery by iontophoresis incorporating enhanced passive diffusion was proposed.
Iontophoretic experiments for transdermal delivery have often been performed using aqueous buffer solutions as a donor and a receptor solution to adjust the pH shift. Although the aqueous buffer system makes it much easier to evaluate the delivery of drug induced by current, it is rather difficult to indicate the enhancement of passive diffusion because of the limited quantities of drug that permeate through the skin in such a system. Furthermore, hydrophobic drugs such as indomethacin are used clinically with alcohol for external pharmaceutical preparations. Therefore, Idomethine KOWA Sol, which exhibits excellent skin permeability, was employed in this study.
Pharmacokinetic Parameters To calculate the pharmacokinetic parameters of indomethacin, Idomethine KOWA Sol was administered to rats by intravenous injection. After an appropriate period, the plasma indomethacin concentration was analyzed by HPLC (Fig. 2) . The AUC was calculated by the trapezoidal method (2176Ϯ423 mg min/ml). Moreover, the systemic clearance, CL, was calculated from the AUC (276Ϯ46 ml/h).
Efficiency of Migration of Indomethacin
To evaluate the efficiency of the distribution of indomethacin, the iontophoretic transdermal delivery of the drug across rat abdominal skin in vivo was examined. After an appropriate period, the plasma indomethacin concentration was analyzed based on the pharmacokinetics (Fig. 3) . The concentration increased with current and time, and the slopes of the plot of the concentration versus time were almost constant. Addi- tionally, the slope increased with an increase of total current as well as reduction of the barrier function of skin.
From the above-mentioned results, the relationship between the plasma concentration 15 min after application and the current was evaluated. The plasma concentration subtracted of that of passive diffusion (without current) was used. The concentration increased with current as shown in Fig. 4 (yϭ1.217x, r 2 ϭ0 .989). The amount of drug transported by the current depends on the intensity of the current. Thus, the amount of indomethacin delivered by enhanced passive diffusion was hypothesized to have a quantitative relationship with the current.
Since the relationship between plasma concentration and current was the same as in the Phipps et al. study, 10) the same analysis was performed. According to Eqs. 8 and 9, the flux (Fiϭ336Ϯ55 mg/h/mA) and the efficiency (Edϭ2.52Ϯ 0.41%) were calculated.
The results were compared to those of Phipps et al., in which the transdermal delivery of pyridostigmine across pig skin was investigated in vivo. The flux and efficiency of drug delivery in the present study were 336 mg/h/mA and 2.52%, while those of Phipps et al. were 1260 mg/h/mA and 19%, a difference of 3.75-fold and 7.54-fold, respectively.
The difference between the studies in experimental conditions given in Table 1 clearly demonstrated that the low molecular weight drug as well as the high donor concentration induced the enhancement of transdermal delivery. Additionally, the delivery of drug increased with an increase of total current. Burning and skin irritation are reported to be induced at a current density of more than 0.5 mA/cm 2 16) and a total current of more than 30 mA min. 17) In this study, there-fore, we employed a drug concentration that was effective and a range of applied currents that avoid burning and skin irritation.
Comparison between Theoretical and Experimental Values
The theoretical and experimental values for the amount of indomethacin delivered was compared. The theoretical value was calculated from the equation proposed by Phipps et al. 10) using the flux and the efficiency of transdermal delivery in vivo. The experimental value was obtained from the sum of the amounts in the skin, muscle and plasma 15 min after application. Results are given in Table 2 . The experimental values were evidently higher than the theoretical ones. The equation proposed by Phipps et al. derived under the hypothesis that a drug migrates immediately into the blood circulation after being transferred to the skin. However, the results observed in this study revealed an accumulation of drug in the skin. The current application as well as the enhancement of passive diffusion may contribute to the delivery of drug in the skin.
The amount of indomethacin distributed by passive diffusion may be given as the difference between the experimental value and theoretical one. As shown in Fig. 5 , the difference, i.e., the amount permeated by passive diffusion, increased linearly as a function of current (yϭ45.416xϩ0.653, r 2 ϭ 0.989). The initial voltage was 4.0, 6.6 and 7.2 V at a current of 0.3, 0.5 and 1.0 mA, respectively. The results suggest that the amount of indomethacin delivered by enhanced passive diffusion increased not only with applied current but also with voltage. In other words, the reduction in skin barrier function depends on both current and voltage. The amount of drug delivered by iontophoresis, M, at processing time, T, is defined in Eq. 10. The proportional constant, k, is changed by dosage forms, solvents, pH, chemical enhancers and applied current. This modified equation may be useful to represent the amount of drug delivered by enhanced passive diffusion as well as the current application.
CONCLUSION
The flux and the efficiency of the transdermal delivery of indomethacin in vivo were calculated using a theory proposed by Phipps et al. The experimental value was evidently higher than the theoretical one. The difference between these values was almost consistent with the amount of indomethacin migrated in the skin. These results suggest that the amount of drug distributed by iontophoresis is the sum of that delivered by current application and by enhanced passive diffusion. Additionally, the amount transported by enhanced passive diffusion was dependent on current and voltage. From these findings, a modified equation for the amount of drug delivered by iontophoresis was proposed. Determining the amount of drug distributed by enhanced passive diffusion is important for iontophoretic transdermal delivery. In this study, the amount transported by iontophoresis could not be well established. Further investigation is needed to understand the reduction in skin barrier function.
